However, although the mean baseline A1C over time has decreased for people with T2D, at the end of the study period, the A1C value was still over 6.5% (the percent at which diabetes is diagnosed) (Centers for Disease Control and Prevention, 2022)
Activating just one produces a moderate growth-hormone pulse
the blend's effect is not established
2025 Aug 4;12(8):e01789
According to FDA labeling for Wegovy (semaglutide), patients should be evaluated after 12 weeks at the maintenance dose (2.4 mg weekly), with discontinuation considered if less than 5% body weight reduction has been achieved
This guide compares the two on mechanism, efficacy, approval status, cost, and side effects, then explains which one fits which situation